

SUPPLEMENTAL INFORMATION STATEMENT TERMINATED MERGER AGREEMENT

AnnaBidiol Corp. (the "Company"), a Delaware corporation trading on the OTC Markets under the symbol ACBD, hereby provides this Supplemental Information Statement pursuant to OTC Markets disclosure requirements.

On July 9, 2024, AnnaBidiol, Corp. (OTC Pink: ACBD) announced in a press release and posted on OTC Markets - a Supplemental Information Disclosure to Report that AnnaBidiol has entered a Merger Agreement with Targatek, Inc., an AI Corporate Leadership SaaS Development Company. In the terms of the agreement, a reverse merger of Targatek Inc. will take place into a newly formed subsidiary of AnnaBidiol, Corp. that will result in the shareholders of Targatek receiving approximately 85% of the common stock of AnnaBidiol, Corp. after approximately 35,000,000 shares of common stock and 500,000 shares of Series A Preferred stock of AnnaBidiol, Inc., to be redeemed and canceled at closing. The merger Agreement provides for the usual and customary warranties and representations and requires the determination that the financials are auditable.

On October 4, 2024, the Company entered into an agreement to acquire Targatek, Inc. and authorized the completion of the merger into a wholly owned subsidiary. However, at and immediately after such date, Targatek provided inaccurate information, failed to fulfill key obligations required for issuing the correct shares in the merger, and failed to deliver accurate financial statements prepared in accordance with Generally Accepted Accounting Principles (GAAP).

On or about October 7, 2025, Targatek Inc. held a board meeting and, at the sole election of Targatek Inc. and its board of directors, elected not to comply with the Agreement and Plan of Merger dated October 4, 2024, and terminated any further discussions or attempts to close under its terms. The decision not to comply with the merger agreement was made unilaterally by Targatek Inc.

Forward-Looking Statements:

This Supplemental Information Statement contains "forward-looking statements" within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, commonly identified by such terms as "believes," "looking ahead," "anticipates," "estimates," and other terms with similar meaning. Specifically, statements about the Company's plans for accelerated growth, improved profitability, future business partners, M&A activity, new service offerings, and pursuit of new markets are forward-looking statements. Although the Company believes that the assumptions upon which its forward-looking statements are based are reasonable, it can give no assurance that these assumptions will prove to be correct. Such forward-looking statements should not be construed as fact. The information contained in such statements is beyond the Company's ability to control. In many cases, the Company cannot predict what factors would cause results to differ materially from those indicated in such statements.

All forward-looking statements in this Supplemental Information Statement are expressly qualified by these cautionary statements and by reference to the underlying assumptions.

{signature page follows}

CERTIFICATION

I, David D. Peralta, Chief Executive Officer (Interim) of AnnaBidiol Corp., certify that:

1. I have reviewed this Supplemental Information Statement of AnnaBidiol Corp., and
2. Based on my knowledge, this Supplemental Information Statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this Supplemental Information Statement.

Date: November 19, 2025

/s/ David D. Peralta
David D. Peralta
Chief Executive Officer (Interim)
AnnaBidiol Corp.